Exclusive Content
China’s 2026 Foreign Investment Action Plan
A source-led review of China’s June 2026 official action plan for stabilizing and optimizing foreign investment and the checks foreign companies should make now.
China Cross-Border Data Flow FAQ for Foreign Companies 2026
Official-source answers to practical cross-border data questions for foreign companies operating with China teams, customers and partners.
China Foreign Investment Entry Rules 2026: Checks Before Choosing a Setup Route
A source-led guide to the official foreign-investment and market-access checks a foreign company should complete before choosing a China setup route.
Sam’s Club Accountability: China’s Food Safety Interview System for Foreign Retailers
After Beijing issued a food safety 'accountability interview' to Walmart's Sam's Club, here is what the process involves and how foreign retailers can stay compliant.
China’s Unicorn Count Hits 381 as ByteDance Ranks Third Globally: Hurun Index
China added 47 new unicorns in H1 2026. ByteDance is now the world's third-most-valuable private company behind OpenAI and Anthropic, while DeepSeek enters the global top 15.
China’s Biotech Boom: 5,215 Clinical Drug Trials in 2025
China registered a record 5,215 clinical drug trials in 2025, up 23% from 2024. This market intelligence briefing covers opportunities, risks, and entry points for foreign pharma and biotech investors.